NY-AQARA
9.4.2024 09:01:58 CEST | Business Wire | Press release
Aqara, a leading provider of smart home solutions, today announced the availability of the Motion and Light Sensor P2, its new generation motion sensor built upon the Thread protocol and the industry-unifying Matter standard. The native Matter connectivity offers unparalleled compatibility across smart home platforms including Amazon Alexa, Apple Home, Google Home, and Samsung SmartThings1. With Matter's local networking capabilities, the P2 sensor ensures enhanced responsiveness and reliability.
“In the rapidly expanding global market for Passive Infrared (PIR) sensors, Aqara has achieved remarkable success, distributing over 100,000 units last year,” states Cathy You, Aqara Senior Vice President, Global Business and Strategy. “The launch of the Motion and Light Sensor P2, which combines our renowned sensor technology with the latest in connectivity protocols and standards, encapsulates our forward-thinking approach and our commitment to delivering smart home solutions that are ready for tomorrow's advancement.”
The Motion and Light Sensor P2 integrates an ultra-wide angle PIR motion sensor with a standalone illumination sensor, providing precise detection up to 7 meters (ca. 23 feet) and 170° horizontally2. This facilitates a range of use scenarios from automated lighting and security enhancement to climate control. The sensor also measures light intensity independently of motion detection3, enabling sophisticated lighting and window covering control for optimal comfort and energy efficiency. Engineered for longevity, the Motion and Light Sensor P2 boasts a robust battery life of up to two years, ensuring dependable operation with minimal maintenance.
As a Thread-enabled device, the Motion and Light Sensor P2 connects to any Matter controller with Thread Border Router functionality, and allows use across multiple compatible platforms thanks to Matter's multi-admin feature. Furthermore, the sensor offers a few Aqara Home exclusive features such as customizable sensitivity and detection timeout settings for tailored performance4. Users can fine-tune both parameters through the Aqara Home app, which requires Aqara's own Thread-enabled Matter controller, for example the upcoming Hub M3.
As part of Aqara’s expanding Thread-enabled product line, the Motion and Light Sensor P2 exemplifies the Company’s dedication to elevating smart home experiences through enhanced interoperability and simplicity. Additional Thread devices from Aqara are expected in the coming months, including the aforementioned Hub M3 and the retrofit home access solution Smart Lock U200.
The Motion and Light Sensor P2 is now available in Aqara’s Amazon brand stores in North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide5.
For more information on this sensor, please visit our website.
1. A Matter controller with Thread Border Router functionality is required for the connection to the corresponding Matter-enabled system.
2. Based on the internal lab test, measured under the ambient temperature of 25 °C (ca. 77 °F) and high sensitivity level.
3. Illumination sensing functionality is not available on Alexa at the time of launch.
4. By default, the sensor is set to medium sensitivity and a 30-second detection timeout.
5. Product availability may vary by retail channel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409809799/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom